Literature DB >> 2292533

In-vitro activity of cefpodoxime against 1834 isolates from domiciliary infections at 20 UK centres.

H A Holt1, M J Bywater, D S Reeves.   

Abstract

A total of 1834 non-copy, general practice or outpatient isolates were collected by 20 hospital laboratories within the British Isles, and identified and tested for susceptibility to nine antimicrobial agents available by oral administration at one centre. Against Enterobacteriaceae cefpodoxime was the most active beta-lactam agent tested, the MIC90s being: for Escherichia coli 1.0 mg/l, for Proteus mirabilis 1.0 mg/l, for Citrobacter spp. 2.0 mg/l, and for Enterobacter spp., Serratia spp., Morganella spp. and Klebsiella spp. 16-64 mg/l. Cefpodoxime also showed a certain amount of activity against staphylococci and high activity against streptococci, the MIC90s being for Staphylococcus aureus 2 mg/l, for coagulase negative staphylococci 8 mg/l, for Streptococcus pyogenes 0.015 mg/l, for Str. pneumoniae 0.06 mg/l and for Str. agalactiae 0.5 mg/l.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2292533     DOI: 10.1093/jac/26.suppl_e.7

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

Review 1.  Cefpodoxime proxetil in the treatment of lower respiratory tract infections.

Authors:  A M Geddes
Journal:  Drugs       Date:  1991       Impact factor: 9.546

2.  In vitro methods for confirming reduced susceptibility to cefuroxime among Haemophilus influenzae isolates.

Authors:  A P MacGowan; M Wootton; P A James; K E Bowker; H A Holt; D S Reeves
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

Review 3.  Cephalosporin utilisation review and evaluation.

Authors:  G M Misan; C Dollman; D R Shaw; N Burgess
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

Review 4.  Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  J E Frampton; R N Brogden; H D Langtry; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.